Type 1 diabetes is a chronic (life-long) autoimmune disease that prevents your pancreas from making insulin. It requires daily management with insulin injections and blood sugar monitoring. Both children and adults can be diagnosed with Type 1 diabetes. Even after a lot of research, type 1 diabetes has no cure. Treatment is directed toward managing the amount of sugar in the blood using insulin, diet and lifestyle to prevent complications.
The global Type 1 Diabetes Medicines market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.
According to IDF data, in 2022, around 8.75 million people with type 1 diabete. Among them, 1.52 million patients are under 20. People with type 1 diabetes require daily insulin treatment, regular blood glucose monitoring and a healthy lifestyle to manage their condition effectively.
This report is a detailed and comprehensive analysis for global Type 1 Diabetes Medicines market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Channel. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Type 1 Diabetes Medicines market size and forecasts, in consumption value ($ Million), 2019-2030
Global Type 1 Diabetes Medicines market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Type 1 Diabetes Medicines market size and forecasts, by Type and by Channel, in consumption value ($ Million), 2019-2030
Global Type 1 Diabetes Medicines market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Type 1 Diabetes Medicines
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Type 1 Diabetes Medicines market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, Sanofi, Eli Lilly, Merck, AstraZeneca, Bayer, Boehringer Ingelheim, Johnson & Johnson, Takeda, Tonghua Dongbao, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Type 1 Diabetes Medicines market is split by Type and by Channel. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Channel. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segmentation
Type 1 Diabetes Medicines market is split by Type and by Channel. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Channel. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Insulin
Others
麻豆原创 segment by Channel
Hospital
Retail Pharmacy
麻豆原创 segment by players, this report covers
Novo Nordisk
Sanofi
Eli Lilly
Merck
AstraZeneca
Bayer
Boehringer Ingelheim
Johnson & Johnson
Takeda
Tonghua Dongbao
United Pharmaceuticals
Ganli Pharmaceutical
Biocon
Wockhardt
Jiangsu Wanbang
Geropharm
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Type 1 Diabetes Medicines product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Type 1 Diabetes Medicines, with revenue, gross margin, and global market share of Type 1 Diabetes Medicines from 2019 to 2024.
Chapter 3, the Type 1 Diabetes Medicines competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Channel, with consumption value and growth rate by Type, by Channel, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Type 1 Diabetes Medicines market forecast, by regions, by Type and by Channel, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Type 1 Diabetes Medicines.
Chapter 13, to describe Type 1 Diabetes Medicines research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Type 1 Diabetes Medicines by Type
1.3.1 Overview: Global Type 1 Diabetes Medicines 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Type 1 Diabetes Medicines Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Insulin
1.3.4 Others
1.4 Global Type 1 Diabetes Medicines 麻豆原创 by Channel
1.4.1 Overview: Global Type 1 Diabetes Medicines 麻豆原创 Size by Channel: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Retail Pharmacy
1.5 Global Type 1 Diabetes Medicines 麻豆原创 Size & Forecast
1.6 Global Type 1 Diabetes Medicines 麻豆原创 Size and Forecast by Region
1.6.1 Global Type 1 Diabetes Medicines 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Type 1 Diabetes Medicines 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Type 1 Diabetes Medicines 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Type 1 Diabetes Medicines 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Type 1 Diabetes Medicines 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Type 1 Diabetes Medicines 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East & Africa Type 1 Diabetes Medicines 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 Novo Nordisk
2.1.1 Novo Nordisk Details
2.1.2 Novo Nordisk Major Business
2.1.3 Novo Nordisk Type 1 Diabetes Medicines Product and Solutions
2.1.4 Novo Nordisk Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Novo Nordisk Recent Developments and Future Plans
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business
2.2.3 Sanofi Type 1 Diabetes Medicines Product and Solutions
2.2.4 Sanofi Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Sanofi Recent Developments and Future Plans
2.3 Eli Lilly
2.3.1 Eli Lilly Details
2.3.2 Eli Lilly Major Business
2.3.3 Eli Lilly Type 1 Diabetes Medicines Product and Solutions
2.3.4 Eli Lilly Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Eli Lilly Recent Developments and Future Plans
2.4 Merck
2.4.1 Merck Details
2.4.2 Merck Major Business
2.4.3 Merck Type 1 Diabetes Medicines Product and Solutions
2.4.4 Merck Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Merck Recent Developments and Future Plans
2.5 AstraZeneca
2.5.1 AstraZeneca Details
2.5.2 AstraZeneca Major Business
2.5.3 AstraZeneca Type 1 Diabetes Medicines Product and Solutions
2.5.4 AstraZeneca Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 AstraZeneca Recent Developments and Future Plans
2.6 Bayer
2.6.1 Bayer Details
2.6.2 Bayer Major Business
2.6.3 Bayer Type 1 Diabetes Medicines Product and Solutions
2.6.4 Bayer Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Bayer Recent Developments and Future Plans
2.7 Boehringer Ingelheim
2.7.1 Boehringer Ingelheim Details
2.7.2 Boehringer Ingelheim Major Business
2.7.3 Boehringer Ingelheim Type 1 Diabetes Medicines Product and Solutions
2.7.4 Boehringer Ingelheim Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Boehringer Ingelheim Recent Developments and Future Plans
2.8 Johnson & Johnson
2.8.1 Johnson & Johnson Details
2.8.2 Johnson & Johnson Major Business
2.8.3 Johnson & Johnson Type 1 Diabetes Medicines Product and Solutions
2.8.4 Johnson & Johnson Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Johnson & Johnson Recent Developments and Future Plans
2.9 Takeda
2.9.1 Takeda Details
2.9.2 Takeda Major Business
2.9.3 Takeda Type 1 Diabetes Medicines Product and Solutions
2.9.4 Takeda Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 Takeda Recent Developments and Future Plans
2.10 Tonghua Dongbao
2.10.1 Tonghua Dongbao Details
2.10.2 Tonghua Dongbao Major Business
2.10.3 Tonghua Dongbao Type 1 Diabetes Medicines Product and Solutions
2.10.4 Tonghua Dongbao Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Tonghua Dongbao Recent Developments and Future Plans
2.11 United Pharmaceuticals
2.11.1 United Pharmaceuticals Details
2.11.2 United Pharmaceuticals Major Business
2.11.3 United Pharmaceuticals Type 1 Diabetes Medicines Product and Solutions
2.11.4 United Pharmaceuticals Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.11.5 United Pharmaceuticals Recent Developments and Future Plans
2.12 Ganli Pharmaceutical
2.12.1 Ganli Pharmaceutical Details
2.12.2 Ganli Pharmaceutical Major Business
2.12.3 Ganli Pharmaceutical Type 1 Diabetes Medicines Product and Solutions
2.12.4 Ganli Pharmaceutical Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.12.5 Ganli Pharmaceutical Recent Developments and Future Plans
2.13 Biocon
2.13.1 Biocon Details
2.13.2 Biocon Major Business
2.13.3 Biocon Type 1 Diabetes Medicines Product and Solutions
2.13.4 Biocon Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.13.5 Biocon Recent Developments and Future Plans
2.14 Wockhardt
2.14.1 Wockhardt Details
2.14.2 Wockhardt Major Business
2.14.3 Wockhardt Type 1 Diabetes Medicines Product and Solutions
2.14.4 Wockhardt Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.14.5 Wockhardt Recent Developments and Future Plans
2.15 Jiangsu Wanbang
2.15.1 Jiangsu Wanbang Details
2.15.2 Jiangsu Wanbang Major Business
2.15.3 Jiangsu Wanbang Type 1 Diabetes Medicines Product and Solutions
2.15.4 Jiangsu Wanbang Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.15.5 Jiangsu Wanbang Recent Developments and Future Plans
2.16 Geropharm
2.16.1 Geropharm Details
2.16.2 Geropharm Major Business
2.16.3 Geropharm Type 1 Diabetes Medicines Product and Solutions
2.16.4 Geropharm Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.16.5 Geropharm Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Type 1 Diabetes Medicines Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Type 1 Diabetes Medicines by Company Revenue
3.2.2 Top 3 Type 1 Diabetes Medicines Players 麻豆原创 Share in 2023
3.2.3 Top 6 Type 1 Diabetes Medicines Players 麻豆原创 Share in 2023
3.3 Type 1 Diabetes Medicines 麻豆原创: Overall Company Footprint Analysis
3.3.1 Type 1 Diabetes Medicines 麻豆原创: Region Footprint
3.3.2 Type 1 Diabetes Medicines 麻豆原创: Company Product Type Footprint
3.3.3 Type 1 Diabetes Medicines 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Type 1 Diabetes Medicines Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Type 1 Diabetes Medicines 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Channel
5.1 Global Type 1 Diabetes Medicines Consumption Value 麻豆原创 Share by Channel (2019-2024)
5.2 Global Type 1 Diabetes Medicines 麻豆原创 Forecast by Channel (2025-2030)
6 North America
6.1 North America Type 1 Diabetes Medicines Consumption Value by Type (2019-2030)
6.2 North America Type 1 Diabetes Medicines 麻豆原创 Size by Channel (2019-2030)
6.3 North America Type 1 Diabetes Medicines 麻豆原创 Size by Country
6.3.1 North America Type 1 Diabetes Medicines Consumption Value by Country (2019-2030)
6.3.2 United States Type 1 Diabetes Medicines 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Type 1 Diabetes Medicines 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Type 1 Diabetes Medicines 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Type 1 Diabetes Medicines Consumption Value by Type (2019-2030)
7.2 Europe Type 1 Diabetes Medicines Consumption Value by Channel (2019-2030)
7.3 Europe Type 1 Diabetes Medicines 麻豆原创 Size by Country
7.3.1 Europe Type 1 Diabetes Medicines Consumption Value by Country (2019-2030)
7.3.2 Germany Type 1 Diabetes Medicines 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Type 1 Diabetes Medicines 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Type 1 Diabetes Medicines 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Type 1 Diabetes Medicines 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Type 1 Diabetes Medicines 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Type 1 Diabetes Medicines Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Type 1 Diabetes Medicines Consumption Value by Channel (2019-2030)
8.3 Asia-Pacific Type 1 Diabetes Medicines 麻豆原创 Size by Region
8.3.1 Asia-Pacific Type 1 Diabetes Medicines Consumption Value by Region (2019-2030)
8.3.2 China Type 1 Diabetes Medicines 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Type 1 Diabetes Medicines 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Type 1 Diabetes Medicines 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Type 1 Diabetes Medicines 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Type 1 Diabetes Medicines 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Type 1 Diabetes Medicines 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Type 1 Diabetes Medicines Consumption Value by Type (2019-2030)
9.2 South America Type 1 Diabetes Medicines Consumption Value by Channel (2019-2030)
9.3 South America Type 1 Diabetes Medicines 麻豆原创 Size by Country
9.3.1 South America Type 1 Diabetes Medicines Consumption Value by Country (2019-2030)
9.3.2 Brazil Type 1 Diabetes Medicines 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Type 1 Diabetes Medicines 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Type 1 Diabetes Medicines Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Type 1 Diabetes Medicines Consumption Value by Channel (2019-2030)
10.3 Middle East & Africa Type 1 Diabetes Medicines 麻豆原创 Size by Country
10.3.1 Middle East & Africa Type 1 Diabetes Medicines Consumption Value by Country (2019-2030)
10.3.2 Turkey Type 1 Diabetes Medicines 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Type 1 Diabetes Medicines 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Type 1 Diabetes Medicines 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Type 1 Diabetes Medicines 麻豆原创 Drivers
11.2 Type 1 Diabetes Medicines 麻豆原创 Restraints
11.3 Type 1 Diabetes Medicines Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Type 1 Diabetes Medicines Industry Chain
12.2 Type 1 Diabetes Medicines Upstream Analysis
12.3 Type 1 Diabetes Medicines Midstream Analysis
12.4 Type 1 Diabetes Medicines Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Novo Nordisk
Sanofi
Eli Lilly
Merck
AstraZeneca
Bayer
Boehringer Ingelheim
Johnson & Johnson
Takeda
Tonghua Dongbao
United Pharmaceuticals
Ganli Pharmaceutical
Biocon
Wockhardt
Jiangsu Wanbang
Geropharm
听
听
*If Applicable.
